Environment, Social and Governance (ESG) at Marinomed
Marinomed is a science-driven company committed to medical progress. It is our vision to alleviate or prevent diseases through continuous research and development. Specifically, our mission is to improve the health of people worldwide and to develop treatments for indications that have no or no adequate treatments so far. In doing so, we are working directly towards Goal 3 of the United Nations Sustainable Development Goals, health for all and well-being for all ages.
Marinomed pursues a highly sustainable business model and has specialised in the research and development of biopharmaceutical products in the therapeutic areas of virology and immunology. After approval (or Declaration of Conformity for medical devices), Marinomed contracts experienced partners via licenses who then produce and distribute these products. Outsourcing these parts of the value chain enables Marinomed to maintain a lean “asset light” business model even when it experiences strong growth. The use of existing production sites and distribution channels helps conserve resources and save costs, keeping the ecological footprint small and thus promoting sustainability.
Sustainable business practices are essential for Marinomed, which is why management is collectively responsible for the planning of strategic development. Important sustainability topics are routinely on the agenda and are regularly addressed by the entire management team and integrated into ongoing projects. The management board firmly believes that long-term economic success can only be achieved if both social and ecological aspects are taken into account. Corporate decisions are made on the basis of this awareness, and processes that are within the Company’s sphere of influence are evaluated at regular intervals in order to continuously increase sustainability in various areas. The supervisory board receives regular reports on the improvement of sustainability.
Marinomed already persecutes a sustainable business model. Our primary goal is to maintain these high standards and raise them even further, wherever possible. This is especially true for our research and development activities and our products. We make a lasting contribution to healthcare. An effective healthcare system with drugs and medical products that can alleviate or heal diseases is in the interests of society as a whole because it affects us all. This is why dialogue with all stakeholders is essential to help us make our contribution to a sustainable future. We will keep having more of these conversations. Our efforts in this regard include reporting that provides wide-ranging information about our sustainability ambitions and achievements. You can find detailed information in our sustainability report:
Marinomeds ESG strategy
ESG Highlights 2021
New Company Headquarter in Korneuburg, AT
SDG 13, 15
- Removal of the sealed surface and added greening to the property
- Thermal renovation of existing buildings
- Environmentally friendly new building and usage of renewable energies
- Fleet almost fully electric
Marinosolv Solubilisation Technology
SDG 3, 9, 17
- Solv4U for technology partnerships
- First partnership for Budesolv
- R&D advances (Indications with high medical need)
Employees & Diversity
SDG 5, 8
- Employee growth +16%
- Investor relations strengthened
- High diversity: again 1st place in the BCG Gender Diversity Index
SDG 3, 9, 17
New partnerships for global availability
Efficacy proven against SARS-CoV-2 variants of concern
Support of the Vienna City Marathon
Marinomed is committed to the guidelines of the Austrian Corporate Governance Code in the version of January 2018 and complies with all provisions required by law (L-Rules) and to a large extent with the provisions required by the Code (C-Rules). C-Rules that have not yet been fully complied with are consistently reviewed and their treatment explained in the Corporate Governance Report.